• AI
  • Molecular Imaging
  • CT
  • X-Ray
  • Ultrasound
  • MRI
  • Facility Management
  • Mammography

Schering’s U.S. sales power first quarter

Article

Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an “exceptionally good” first quarter 2000, the company said last week.U.S. sales grew by 49% to 231 million euros, accounting for 22%

Sales of drugs and contrast agents in the U.S. drove German pharmaceuticals maker Schering to what it called an “exceptionally good” first quarter 2000, the company said last week.

U.S. sales grew by 49% to 231 million euros, accounting for 22% of Schering’s total sales, which were reported up 25% to 1.044 billion euros. Net profit was up 22% to 106 million euros ($97.5 million) in the period from January to March.

The company’s diagnostics division, which is one of the world’s largest makers of contrast agents, showed a sales increase of 27% to 295 million euros. Schering also makes a best-selling multiple sclerosis drug, Betaferon, and is a leading manufacturer of contraceptives and fertility drugs.

Related Videos
Does Initial CCTA Provide the Best Assessment of Stable Chest Pain?
Making the Case for Intravascular Ultrasound Use in Peripheral Vascular Interventions
Can Diffusion Microstructural Imaging Provide Insights into Long Covid Beyond Conventional MRI?
Assessing the Impact of Radiology Workforce Shortages in Rural Communities
Emerging MRI and PET Research Reveals Link Between Visceral Abdominal Fat and Early Signs of Alzheimer’s Disease
Reimbursement Challenges in Radiology: An Interview with Richard Heller, MD
Nina Kottler, MD, MS
The Executive Order on AI: Promising Development for Radiology or ‘HIPAA for AI’?
Related Content
© 2024 MJH Life Sciences

All rights reserved.